Abstract Library

#2823 Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours

Introduction: Neuroendocrine tumours (NETs) arising from the rectum are more common in the Asian population. Current treatment options include somatostatin analogues, chemotherapy, and more recently, peptide-receptor radionuclide therapy (PRRT). Peptide receptor radionuclide therapy (PRRT) has been shown to be effective in the treatment of advanced gastroenteropancreatic (GEP) tumours with minimal adverse effects. Studies have also suggested that rectal NETs show good response to PRRT, better than GEP NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Tham W, Huang H, Tai W, Yan X, Ng C,

Keywords: Neuroendocrine tumours, PRRT,

#2819 Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue

Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: De Felice I, Rinzivillo M, Pratesi M, Magi L, Annibale B,

Keywords: Pancreatic Exocrine Insufficiency,

#2744 Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review

Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wee C, Dundar A, Packard A, Kendi A, Eiring R,

Keywords: prrt, peptide receptor radionuclide therapy,

#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors

Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tan H

Authors: Wang X, Li Y, Shi Y, Chen Y, Qiu X,

Keywords: thymic neuroendocrine tumors, capecitabine, temozolomide, progress-free survival, adverse effect,

#1125 Efficacy of PRRT in Metastatic Neuroendocrine Tumors; A Retrospective Large Single Institutional Study

Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Jan H

Authors: Jan H, Wyld D, Burge M,

Keywords: lutetium, somatostatin receptor, PRRT, neuroendocrine tumors,